AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RAPP

Silva Paul M purchased $100K of RAPP (indirect holdings)

Silva Paul M purchased 3,680 indirectly-held shares of Rapport Therapeutics, Inc. (RAPP) at $27.08 on 2026-10-22.

Original reporting
SEC EDGAR · Silva Paul M
Published Oct 22, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Neutral
medium confidence
Mentioned
$RAPP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPNeutralLow
01

Why it matters

The $100K purchase is a modest signal; traders may monitor subsequent insider activity for larger trends.

02

Market read

The filing provides a fresh data point on insider confidence but is unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical milestones or financing events not disclosed in the filing.

Relevance 4/10Novelty 6/10Timing: same-day filing

Background

Form 4 filings disclose insider transactions and are used by investors to gauge insider sentiment.

Company-level read

Ticker impact

$RAPPNeutralMedium confidence
Context

Director Silva Paul M purchased 3,680 shares of Rapport Therapeutics at $27.075 per share, filing a Form 4 on 2026-10-22.

Expected impact

potential slight upside as market prices in insider confidence

Evidence & confidence

The transaction is a primary disclosure (Form 4) but the dollar size is small, limiting material impact.

Market effects

Sector

Minimal effect on biotech sector; insider activity is routine.

Regional

No regional impact beyond the company's own stock.

Global

Limited to investors tracking insider activity in small-cap biotech.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong bullish signal.

Key entities

  • Company
    Rapport Therapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker RAPP.

  • Individual
    Silva Paul M

    Director of Rapport Therapeutics who filed the insider purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

tradingview.com
$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

SEC EDGAR 8-K
$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.

finance.yahoo.com